Brigitte Michelsen Selected Research

C-Reactive Protein

4/2024	ASDAS-CRP and ASDAS-ESR cut-offs for disease activity states in axial spondyloarthritis - Are they interchangeable?
9/2023	Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching.
8/2022	Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study.
1/2022	Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
12/2018	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?
1/2018	Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.
1/2018	DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brigitte Michelsen Research Topics

Disease

19	Psoriatic Arthritis 04/2024 - 01/2017
12	Axial Spondyloarthritis 04/2024 - 01/2020
10	Pain (Aches) 01/2024 - 01/2018
8	Rheumatoid Arthritis 01/2022 - 01/2017
7	Ankylosing Spondylitis 04/2024 - 01/2020
7	Fatigue 01/2024 - 01/2020
4	Arthritis (Polyarthritis) 02/2023 - 01/2022
4	Necrosis 11/2021 - 01/2017
3	Ulcerative Colitis 01/2023 - 01/2021
3	Crohn Disease (Crohn's Disease) 01/2023 - 01/2021
2	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2021 - 01/2021
2	Inflammation (Inflammations) 05/2021 - 11/2020
2	Arthralgia (Joint Pain) 05/2021 - 11/2017
1	Rheumatic Diseases (Rheumatism) 02/2023
1	Non-Radiographic Axial Spondyloarthritis 01/2023
1	Infections 01/2023
1	Uveitis 01/2023
1	Neoplasms (Cancer) 12/2022
1	Spondylarthritis (Spinal Arthritis) 11/2022
1	Acute Coronary Syndrome 01/2022
1	Joint Diseases (Joint Disease) 01/2020

Drug/Important Bio-Agent (IBA)

18	Tumor Necrosis Factor InhibitorsIBA 05/2024 - 01/2020
13	Antirheumatic Agents (DMARD)IBA 01/2023 - 01/2017
7	C-Reactive ProteinIBA 04/2024 - 01/2018
7	secukinumabIBA 01/2024 - 01/2020
4	ametantrone (HAQ)IBA 01/2024 - 10/2022
3	Adalimumab (Humira)FDA Link 01/2023 - 01/2023
2	Prostaglandins AIBA 01/2024 - 11/2022
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 08/2022 - 05/2021
2	ORALIT (ORS)IBA 01/2022 - 01/2021
2	Infliximab (Remicade)FDA Link 12/2021 - 01/2021
2	1- hydroxy- 5,8- bis(2- ((2- hydroxyethyl)amino)ethylamino)- 9,10- anthracenedioneIBA 05/2021 - 01/2020
2	Methotrexate (Mexate)FDA LinkGeneric 11/2017 - 01/2017
1	Ustekinumab (CNTO 1275)FDA Link 01/2023
1	tofacitinibIBA 01/2023
1	apremilastIBA 01/2023
1	ixekizumabIBA 01/2023
1	Etanercept (Enbrel)FDA Link 01/2023
1	Abatacept (Orencia)FDA Link 01/2023
1	insulin receptor-related receptor (IRR)IBA 12/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2022
1	AntibodiesIBA 08/2022
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	Rheumatoid FactorIBA 11/2020
1	Anti-Citrullinated Protein AntibodiesIBA 11/2020
1	golimumab FDA Link 01/2020
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 11/2017

Therapy/Procedure

5	Therapeutics 01/2023 - 11/2020